SecBot SecBot
SECBOTREPLAY Home › Report › ARTV

ARTV · Four Artiva Biotherapeutics insiders, including the CEO, COO, and CTO,…

Artiva Biotherapeutics, Inc. · CLUSTER filed Sep 9, 2026 at 16:02 ET

At the news

NEUTRALIMPACT 3/10

CLUSTER filed Sep 9, 2026 at 16:02 ET

Four Artiva Biotherapeutics insiders, including the CEO, COO, and CTO, sold a total of ~$477K in open-market shares over a one-week window. These sales follow a cluster of non-cash equity grants to the same executives, suggesting the sales are likely liquidity-driven (tax planning, diversification) rather than signaling a bearish view on the company's pipeline. The total dollar value is ~0.1% of the $500M market cap, falling at the low end of the trivial-to-modest range, and the historical pattern of insider buys at this company has been strongly predictive of upside, not sales. The cross-filing context shows no bearish corporate events (no earnings miss, no restructuring, no late filing) that would amplify the signal, and the actuarial verdicts confirm that insider-sale clusters without such context are not amplified. The net impact is neutral to slightly cautious, but not a material sell signal.

  • CEO Fred Aslan sold 23.4K shares for ~$256K on 2026-09-08 at $10.92/share.
  • COO Jennifer Bush sold 8.4K shares for ~$94K on 2026-09-03 at $11.16/share.
  • CTO Christopher Horan sold 10.4K shares for ~$116K on 2026-09-03 at $11.16/share.
  • CMO Subhashis Banerjee sold 1.1K shares for ~$12K on 2026-09-03 at $11.16/share.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access